<DOC>
	<DOCNO>NCT00416533</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , doxorubicin , prednisone , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel , doxorubicin , prednisone together work treat patient advanced prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Docetaxel , Doxorubicin , Prednisone Treating Patients With Advanced Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess prostate specific antigen response rate docetaxel , doxorubicin hydrochloride , prednisone patient hormone-refractory advanced prostate cancer . Secondary - Assess treatment docetaxel , doxorubicin hydrochloride , prednisone improve health-related quality life patient . - Assess toxicity docetaxel , doxorubicin hydrochloride , prednisone . - Assess response rate measurable disease . OUTLINE : Patients receive docetaxel IV 1 hour day 1 , doxorubicin hydrochloride IV 15 minute day 1 8 , oral prednisone daily day 1-21 . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 course , completion 3 course , disease progression . After complete study treatment , patient follow every 6 month 1 year . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate following : Prostatespecific antigen ≥ 10 mg/dL Bone disease Bidimensional soft tissue disease Evaluable disease Advanced disease AND fail prior primary androgen ablation therapy , include antiandrogen withdrawal Disease amenable local curative treatment No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine &lt; 2.0 mg/dL SGPT SGOT &lt; 1.5 time upper limit normal ( ULN ) Bilirubin ≤ ULN Hemoglobin ≥ 10 g/dL Ejection fraction ≥ 50 % Peripheral neuropathy ≤ grade 1 Fertile patient must use effective contraception 3 month completion study treatment No previous history concurrent malignancy , except follow : Inactive nonmelanoma skin cancer Diseasefree five year Adequately treat stage I II cancer patient currently complete remission No serious medical illness would limit survival less 3 month No psychiatric condition would prevent informed consent No active , uncontrolled bacterial , viral , fungal infection No hemorrhagic disorder No history severe hypersensitivity reaction drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : See Disease Characteristics No new hormonal treatment within past 4 week No prior immunotherapy , chemotherapy , boneseeking radiopharmaceutical ( e.g. , strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium ) Prior bisphosphonates allow At least 2 week since prior radiotherapy No concurrent chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>